首页> 外文OA文献 >Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer

【2h】

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer

机译：keynote-158研究，FDA授予Pembrolizumab的加速批准用于治疗晚期PD-L1阳性宫颈癌患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Edith Borcoman; Christophe Le Tourneau;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study [J] . Chung Hyun Cheol, Ros Willeke, Delord Jean-Pierre, Journal of Clinical Oncology . 2019,第17期

机译：Pembrolizumab在先前治疗的晚期宫颈癌中的功效和安全性：II期主题-158研究的结果
2. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy [J] . Suzman Daniel L., Agrawal Sundeep, Ning Yang‐min, The oncologist . 2019,第4期

机译：FDA批准摘要：Atezolizumab或Pembrolizumab用于治疗患有先进的尿液癌患者的患者，不允许含Cisplatin的化疗
3. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy [J] . Daniel L. Suzman, Kirsten B. Goldberg, Amna Ibrahim, The oncologist . 2019,第4期

机译：FDA批准摘要：Atezolizumab或Pembrolizumab用于治疗患有先进的尿液癌患者的患者，不允许含Cisplatin的化疗
4. A feasibility study of IMRT for the treatment of cervical cancer patients unable to receive intracavitary brachytherapy [C] . Roeske, J.C., Lujan, Engineering in Medicine and Biology Society, 2000. Proceedings of the 22nd Annual International Conference of the IEEE . 2000

机译：IMRT治疗无法接受腔内近距离放射治疗的宫颈癌患者的可行性研究
5. Treatment Patterns and Cost-Effectiveness of Chemotherapy Treatments among Advanced Gastric Cancer Patients [D] . Haag, Austin Jade. 2017

机译：晚期胃癌患者化学疗法的治疗模式和成本效益
6. Keynote-158 study FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer [O] . Edith Borcoman, Christophe Le Tourneau 2020

机译：keynote-158研究FDA授予Pembrolizumab的加速批准用于治疗晚期PD-L1阳性宫颈癌患者
7. 254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer [O] . D. Lorusso, Y. Xiang, N. Colombo, 2020

机译：254TIP engot-CX11 / Keynote-A18：具有高风险局部晚期宫颈癌患者的蛋白质，随机，随机的双盲研究蛋白质疗法

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer

著录项

引文网络

相似文献

相关主题

期刊订阅